Lantern Pharma Inc
LTRN3.260USD
+0.020+0.62%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
35.99MMarket Cap
LossP/E TTM
More Details of Lantern Pharma Inc Company
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma Inc Info
Ticker SymbolLTRN
Company nameLantern Pharma Inc
IPO dateJun 11, 2020
CEOSharma (Panna L)
Number of employees24
Security typeOrdinary Share
Fiscal year-endJun 11
Address1920 Mckinney Avenue
CityDALLAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75201
Phone19722771136
Websitehttps://www.lanternpharma.com/
Ticker SymbolLTRN
IPO dateJun 11, 2020
CEOSharma (Panna L)
Company Executives of Lantern Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
Other
72.28%
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
Other
72.28%
Shareholder Types
Shareholders
Proportion
Corporation
13.19%
Venture Capital
9.08%
Investment Advisor
7.80%
Investment Advisor/Hedge Fund
2.08%
Hedge Fund
1.49%
Individual Investor
0.41%
Research Firm
0.09%
Other
65.86%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
75
2.28M
21.15%
-484.54K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
1.08M
9.96%
-157.85K
-12.79%
Jun 30, 2025
Biological Mimetics, Inc
844.13K
7.82%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.84%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Jun 30, 2025
CM Management, LLC
200.00K
1.85%
--
--
Jun 30, 2025
Renaissance Technologies LLC
90.60K
0.84%
+1.80K
+2.03%
Jun 30, 2025
Geode Capital Management, L.L.C.
91.89K
0.85%
+1.39K
+1.53%
Jun 30, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Jun 30, 2025
GWM Advisors LLC
56.51K
0.52%
-3.42K
-5.70%
Jun 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
--
--
Jul 23, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Lantern Pharma Inc?
The top five shareholders of Lantern Pharma Inc are:
Bios Equity Partners, LP. holds 1.08M shares, accounting for 9.96% of the total shares.
Biological Mimetics, Inc holds 844.13K shares, accounting for 7.82% of the total shares.
Prophase Labs Inc holds 631.20K shares, accounting for 5.84% of the total shares.
The Vanguard Group, Inc. holds 363.72K shares, accounting for 3.37% of the total shares.
CM Management, LLC holds 200.00K shares, accounting for 1.85% of the total shares.
Bios Equity Partners, LP. holds 1.08M shares, accounting for 9.96% of the total shares.
Biological Mimetics, Inc holds 844.13K shares, accounting for 7.82% of the total shares.
Prophase Labs Inc holds 631.20K shares, accounting for 5.84% of the total shares.
The Vanguard Group, Inc. holds 363.72K shares, accounting for 3.37% of the total shares.
CM Management, LLC holds 200.00K shares, accounting for 1.85% of the total shares.
What are the top three shareholder types of Lantern Pharma Inc?
The top three shareholder types of Lantern Pharma Inc are:
Bios Equity Partners, LP.
Biological Mimetics, Inc
Prophase Labs Inc
Bios Equity Partners, LP.
Biological Mimetics, Inc
Prophase Labs Inc
How many institutions hold shares of Lantern Pharma Inc (LTRN)?
As of 2025Q3, 75 institutions hold shares of Lantern Pharma Inc, with a combined market value of approximately 2.28M, accounting for 21.15% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.91%.
What is the biggest source of revenue for Lantern Pharma Inc?
In --, the -- business generated the highest revenue for Lantern Pharma Inc, amounting to -- and accounting for --% of total revenue.
